<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02089087</url>
  </required_header>
  <id_info>
    <org_study_id>CCFZ533X2101</org_study_id>
    <nct_id>NCT02089087</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CFZ533 in Healthy Subjects and Rheumatoid Arthritis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human study to investigate the safety, tolerability, pharmacokinetics, and
      pharmacodynamics of single intravenous and subcutaneous doses of CFZ533 in healthy subjects
      and intravenous doses in rheumatoid arthritis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Healthy Volunteer only study originally, but after an amendment to protocol,
      rheumatoid arthritis patients will be starting 7-Mar-2014 and thus, the protocol is now
      registered.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 7, 2013</start_date>
  <completion_date type="Actual">February 3, 2017</completion_date>
  <primary_completion_date type="Actual">February 3, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events as a measure of safety and tolerability</measure>
    <time_frame>7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of CFZ533: Area Under the Plasma Concentration-time Curve (AUC)</measure>
    <time_frame>6 months</time_frame>
    <description>The following PK parameters were determined from the plasma concentration time profile of CFZ533 using a non-compartmental method:
AUCtau: Area under the plasma concentration-time curve from time zero to the end of the dosing interval
AUClast: Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration
AUCinf: Area under the plasma concentration-time curve from time zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of CFZ533: Observed Maximum Plasma Concentration Following Drug Administration (Cmax)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of CFZ533: Systemic Clearance from Plasma (CL)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of CFZ533: Apparent Volume of Distribution (Vss)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CFZ533 immunogenicity</measure>
    <time_frame>6 months</time_frame>
    <description>Determining the presence and measuring amount of anti-CFZ533 antibodies in the blood</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>CFZ533 in healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CFZ533 single dose in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CFZ533 in rheumatoid arthritis patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CFZ533 single dose in rheumatoid arthritis patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CFZ533</intervention_name>
    <description>Single dose at varying dosage levels depending on treatment assignment</description>
    <arm_group_label>CFZ533 in healthy volunteers</arm_group_label>
    <arm_group_label>CFZ533 in rheumatoid arthritis patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (for healthy volunteers):

          1. Healthy male and surgically sterilized or post-menopausal female subjects 18 to 55
             years of age (for Cohort 9 only, subjects must be of Chinese descent)

          2. Vital signs (systolic and diastolic blood pressure and pulse rate) should be within
             normal limits

          3. Weight 50-150 kg and a body mass index (BMI) 18-32 kg/m2

        Inclusion Criteria (for rheumatoid arthritis patients):

          1. Healthy male and surgically sterilized or post-menopausal female subjects 18 to 55
             years of age

          2. Fulfilled 2010 ACR/EULAR classification criteria for RA per Investigator

          3. Treatment with a stable oral RA treatment regimen for ≥ 4 weeks before randomization

          4. Systemic corticosteroids allowed if on a stable dose (≤ 10 mg/day of prednisone or
             equivalent) ≥ 4 weeks prior to randomization

          5. Subjects taking NSAIDs (COX-1 or COX-2 inhibitors) as part of their RA therapy must be
             on a stable dose for at least 4 weeks before randomization

        Exclusion Criteria (for healthy volunteers):

          1. History of hypersensitivity to vaccines, the study drug, or to drugs of similar
             chemical classes (i.e., biologic agents)

          2. Abnormal hematology, coagulation or inflammatory lab results

          3. History or evidence of tuberculosis.

        Exclusion Criteria (for rheumatoid arthritis patients):

          1. Use of anti-TNF or other biologics in previous 3 months

          2. Any intra-articular injection therapy (e.g., corticosteroid, hyaluronan) required for
             treatment of acute RA flare within 4 weeks before randomization

          3. Previous treatment with a B cell-depleting biologic agent or any other
             immunomodulatory biologic agent within 5 half-lives (experimental or approved)

          4. Current treatment with cyclophosphamide

          5. Autoimmune disease other than RA

          6. Adult juvenile rheumatoid arthritis

          7. RA functional status class IV according to the ACR 1991 revised criteria

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207-5710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2014</study_first_submitted>
  <study_first_submitted_qc>March 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2014</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid arthritis, RA, first-in-human, single ascending dose, safety, tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

